U.S. dollar banknotes and medicines are seen in this illustration taken, June 27, 2024. REUTERS/Dado Ruvic/Illustration

Scholar Rock Holding Corp priced its newly approved spinal muscular atrophy treatment at $310,000 annually per typical patient. The therapy is the first approved treatment targeting muscle loss in the disorder. Shares rose 5% following the announcement.